Fritextsökning
Innehållstyper
-
MVA:s CEO: “Our investments should improve people´s everyday lives”
Involuntary infertility and diabetes are two of the areas on the agenda of the Medicon Valley Alliance.
-
He is heading a new company for the development of Coegin’s cancer drug
The biotechnology company Coegin Pharma places the development of its drug candidate AVX420 in a newly formed company, Avexxin Oncology, based in Norway, and Jo...
-
Mikael Kubista tillbaka med ny satsning – efter turbulenta avskedet
Entreprenören och forskaren Mikael Kubista startar ett nytt bolag. Nu är han också fri att kommentera händelseförloppet som ledde till att han förlorade ägandet...
-
Bio-Works
-
A green nursery for biotech rooted in the Scanian soil
Red Glead has established itself as one of Lund’s largest companies in pharmaceutical development. Life Science Sweden went to Skåne and met two of the founders...
-
“We need to keep investing in research and innovation”
Jenni Nordborg has worked for just over four years to highlight life science in Sweden. Her mandate as national coordinator ends in December 2022. ““Life scienc...
-
New study: Post-Covid symptoms are common even after mild Covid-19
According to researchers at the University of Gothenburg, loss of smell and taste, shortness of breath and chest symptoms are the most common complaints after a...
-
Combining two drug delivery strategies to improve bioavailability
Danish researchers hope to increase the bioavailability of low solubility drugs.
-
Biosimilars bring price pressure, but are they sufficiently used?
When biosimilars were introduced just over 16 years ago, hopes were raised that they would give many more patients access to effective but otherwise extremely e...
-
Pfizer’s record year – topped the $100 billion mark
In 2022 Pfizer, as the first pharmaceutical company in history, reached an annual revenue of more than 100 billion dollars, thereby surpassing Johnson & Johnson...
-
ZEISS Metrology Shop provides planning security
ZEISS Metrology Shop brings it all together.
-
Pfizer slutar sälja uppmärksammad genterapi
Pfizer kommer att avbryta utvecklingen och försäljningen av sin uppmärksammade och extremt dyra genterapi mot blödarsjuka, Beqvez. Orsaken uppges vara bristande efterfrågan.
-
Bought a tablet factory – and built his own empire
In 1995, Thomas Eldered was CEO of one of Pharmacia’s factories in the Stockholm area when the Swedish pharmaceutical giant, after a takeover, decided to move i...
-
Great Swedish innovations: Eye treatment became a feather in Pharmacia’s cap
From complicated and sometimes risky surgery to a routine procedure. Pharmacia’s injectable Healon revolutionised the field of eye surgery - and is considered b...
-
Novavax is developing a vaccine candidate against Covid-19 and seasonal flu
A combined vaccine against both Covid-19 and seasonal flu is showing promising results in studies, according to the American drug developer Novavax. The adjuvan...
-
FOKUS Patient turns international
FOKUS Patient is arranging conferences over 3 days in October, and this year, the focus will be on international collaborations.
-
Column: Repurposing as a golden ticket to approval
"Hopefully, in the end, patients will be winners by receiving on-label treatments for which benefit-risk has been properly assessed." In a column Marie Gårdmark...
-
Webinar: Medtech quality and regulatory compliance
This webinar is for you who are developing or planning to develop a medical device, combination, or borderline product. In one hour, we will discuss what you ne...
-
Anders Blanck about his 17 years at Lif: “The industry is enjoying greater public trust now"
The announcement came as a surprise to those around him, but according to the protagonist himself, the timing was excellent. Anders Blanck is now leaving Lif – ...
-
Column: Why there cannot be a complete cure for cancer – but there is certainly another way!
"Is there a new way we need to be thinking about how to prevent cancer?" Lucy Robertshaw reflects upon which is the smartest way to beat cancer.
-
Unexpected study results on testosterone – no reduction in fracture risk
Testosterone treatment is known to increase bone density and bone quality. However, a study now suggests that supplementation with the male sex hormone does not...
-
BioVentureHub CEO: “Companies with a high degree of interaction achieve greater success”
For the first time since its inception, AstraZeneca’s BioVentureHub can now recruit new companies, as some of its tenants have grown significantly and are leavi...
-
Cytel Inc acquires the SDS Group
The multinational statistical software developer and contract research organization Cytel Inc, headquartered in Massachusetts, USA, acquires the Swedish consult...
-
ZEISS presents the "Quality Innovation Summit"
A global event on the future of quality assurance.